Kelun-Biotech says China regulator accepts sac-TMT filing for first-line metastatic TNBC usePUBT·1 day ago, 04:01 AM06990+0.58%
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | CBIO Stock NewsStockTitan·1 day ago, 10:35 PMCBIO-6.32%06990+0.58%
Kelun-Biotech wins China IND clearance for SKB565 in advanced solid tumorsPUBT·Jul 27 at 05:43 AM06990+0.58%
Nomura Raises SKB BIO TP to HKD612.66, Settlement Payment to Drive Mid-term Turnaround; Maintains BuyAASTOCKS News·Jul 26 at 11:27 PM06990+0.58%
SPDB Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)Tip Ranks·Jul 21 at 05:57 AM06990+0.58%
Capital Rotation in Hong Kong: Operational Updates on 10 Utilities, Biotech, and Consumer EquitiesGlobal Report·Jul 21 at 04:13 AM01635+2.17%01164+3.42%
JPM Raises SKB BIO TP to HKD648 as Company Research Achieves Positive ResultsAASTOCKS News·Jul 17 at 03:30 AM06990+0.58%
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyPharmaceutical Technology·Jul 16 at 03:59 AM06990+0.58%02142+4.19%
China NMPA clears Kelun-Biotech, Harbour BioMed asthma IND for SKB575/HBM7575PUBT·Jul 15 at 05:02 AM06990+0.58%02142+4.19%
